Patents by Inventor Svitlana Kulyk

Svitlana Kulyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for Separation of Enantiomers
    Publication number: 20250019367
    Abstract: The present invention relates to methods for separating enantiomers of 5-phenyl and 5-naphthyl substituted 4-(aminomethyl)-6-(1-methyl-1H-pyrazol-4-yl)phthalazin-1(2H)-ones using N-Boc-L-phenylalanine, N-Boc-D-phenylalanine, and similar chiral acids.
    Type: Application
    Filed: October 6, 2022
    Publication date: January 16, 2025
    Inventors: Michal Achmatowicz, Svitlana Kulyk, David Snead, Cheng Chen, Matthew Marx, Christopher Smith
  • Compounds and methods for modulating HER2
    Patent number: 12145948
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, A, E1, E2, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: December 1, 2023
    Date of Patent: November 19, 2024
    Assignee: IAMBIC THERAPEUTICS, INC.
    Inventors: Svitlana Kulyk, Shawn Wright, Joseph Dennis, Wallace Derricotte, Iriny Botrous, Laurent Gomez
  • TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS
    Publication number: 20240376127
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: April 24, 2024
    Publication date: November 14, 2024
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
    Publication number: 20240368153
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: June 29, 2022
    Publication date: November 7, 2024
    Inventors: Christopher Ronald Smith, Svitlana Kulyk, Matthew Arnold Marx, John David Lawson, Anthony Ivetac, Xiaolun Wang, Aaron Craig Burns
  • CRYSTALLINE FORMS OF 2-(4-(4-(AMINOMETHYL)-1-OXO-1,2-DIHYDROPHTHALAZIN-6-YL)-1-METHYL-1H-PYRAZOL-5-YL)-4-CHLORO-6-CYCLOPROPOXY-3-FLUOROBENZONITRILE
    Publication number: 20240270719
    Abstract: Disclosed herein are crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile free base, pharmaceutically acceptable compositions comprising these crystalline forms, and methods for using these crystalline forms.
    Type: Application
    Filed: February 9, 2024
    Publication date: August 15, 2024
    Inventors: Michal Achmatowicz, Svitlana Kulyk, Christopher Ronald Smith, Nan Wang, Harsh Shah, Tian Xie, Qi Gao
  • MTA-Cooperative PRMT5 Inhibitors
    Publication number: 20240208912
    Abstract: Disclosed are compounds of Formula IIA, IA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in methods and pharmaceutical compositions for treating cancer.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 27, 2024
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • COMPOUNDS AND METHODS FOR MODULATING HER2
    Publication number: 20240182494
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, A, E1, E2, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Application
    Filed: December 1, 2023
    Publication date: June 6, 2024
    Inventors: Svitlana KULYK, Shawn WRIGHT, Joseph DENNIS, Wallace DERRICOTTE, Iriny BOTROUS, Laurent GOMEZ
  • Tetrahydropyridopyrimidine pan-KRas inhibitors
    Patent number: 11999753
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: June 4, 2024
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • COMPOUNDS AND METHODS FOR MODULATING HER2
    Publication number: 20240132521
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, A, E1, E2, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Application
    Filed: August 22, 2023
    Publication date: April 25, 2024
    Inventors: Svitlana KULYK, Shawn WRIGHT, Joseph DENNIS, Wallace DERRICOTTE, Iriny BOTROUS, Laurent GOMEZ
  • QUINAZOLINE PAN-KRas INHIBITORS
    Publication number: 20240025907
    Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: August 2, 2023
    Publication date: January 25, 2024
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • SUBSTITUTED PYRIMIDINES AND METHODS OF USE
    Publication number: 20230399312
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Application
    Filed: April 27, 2023
    Publication date: December 14, 2023
    Inventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
  • ALK5 inhibitors
    Patent number: 11730720
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: August 22, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Svitlana Kulyk, Christina Owens, Steven D. E. Sullivan, Jennifer Kozak, Adam D. Hughes
  • SOS1 inhibitors
    Patent number: 11702418
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: July 18, 2023
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang, Svitlana Kulyk, Anthony Ivetac
  • SUBSTITUTED PYRIDINES AND METHODS OF USE
    Publication number: 20230218597
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Application
    Filed: January 4, 2023
    Publication date: July 13, 2023
    Inventors: Christina Owens, Svitlana Kulyk, Steven D.E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Chen Zhao, Erik Fenster, Adam D. Hughes
  • Substituted pyrimidines and methods of use
    Patent number: 11673879
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: June 13, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
  • SOS1 INHIBITORS
    Publication number: 20230137886
    Abstract: The present invention relates to methods of treating cancer using compounds that inhibit Son of sevenless homolog 1 (SOS1) activity and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: November 29, 2022
    Publication date: May 4, 2023
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang, Svitlana Kulyk, Anthony Ivetac
  • Azaquinazoline pan-KRas inhibitors
    Publication number: 20230072276
    Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: December 15, 2021
    Publication date: March 9, 2023
    Inventors: Xiaolun Wang, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • Substituted pyridines and methods of use
    Patent number: 11590116
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: February 28, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Christina Owens, Svitlana Kulyk, Steven D. E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Erik Fenster, Adam D. Hughes
  • MTA-Cooperative PRMT5 Inhibitors
    Publication number: 20230054883
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: September 12, 2022
    Publication date: February 23, 2023
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • SUBSTITUTED PYRIMIDINES AND METHODS OF USE
    Publication number: 20220372015
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Application
    Filed: March 30, 2021
    Publication date: November 24, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes